Stock Traders Purchase High Volume of TG Therapeutics Call Options (NASDAQ:TGTX)

Posted by Defense World Staff on Apr 11th, 2023

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Rating) was the recipient of some unusual options trading activity on Monday. Stock traders bought 13,305 call options on the company. This represents an increase of 40% compared to the average daily volume of 9,518 call options.

Analyst Ratings Changes

A number of brokerages recently issued reports on TGTX. StockNews.com started coverage on TG Therapeutics in a report on Thursday, March 16th. They set a “sell” rating on the stock. Cantor Fitzgerald boosted their target price on shares of TG Therapeutics from $18.00 to $24.00 and gave the stock an “overweight” rating in a report on Tuesday, February 7th. Evercore ISI increased their price target on shares of TG Therapeutics from $16.00 to $25.00 and gave the company an “outperform” rating in a report on Tuesday, January 24th. B. Riley increased their target price on shares of TG Therapeutics from $17.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, December 30th. Finally, Bank of America boosted their target price on TG Therapeutics from $5.00 to $6.00 and gave the company an “underperform” rating in a research report on Thursday, December 29th. Three research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat, TG Therapeutics has an average rating of “Hold” and an average price target of $18.00.

Institutional Trading of TG Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Advisor Group Holdings Inc. lifted its holdings in shares of TG Therapeutics by 49.5% during the first quarter. Advisor Group Holdings Inc. now owns 34,433 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 11,406 shares during the last quarter. Raymond James & Associates increased its position in shares of TG Therapeutics by 4.3% during the 1st quarter. Raymond James & Associates now owns 165,994 shares of the biopharmaceutical company’s stock worth $1,579,000 after purchasing an additional 6,860 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of TG Therapeutics by 28.3% in the first quarter. HighTower Advisors LLC now owns 13,603 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 2,998 shares during the last quarter. MetLife Investment Management LLC increased its position in TG Therapeutics by 59.0% in the first quarter. MetLife Investment Management LLC now owns 71,269 shares of the biopharmaceutical company’s stock worth $678,000 after purchasing an additional 26,443 shares during the period. Finally, BlackRock Inc. lifted its stake in TG Therapeutics by 0.4% in the first quarter. BlackRock Inc. now owns 8,935,578 shares of the biopharmaceutical company’s stock valued at $84,978,000 after buying an additional 33,413 shares during the period. 68.06% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $19.01 on Tuesday. The stock has a market capitalization of $2.78 billion, a P/E ratio of -13.02 and a beta of 2.07. TG Therapeutics has a fifty-two week low of $3.48 and a fifty-two week high of $19.59. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.16 and a current ratio of 3.16. The company has a 50 day moving average price of $16.36 and a 200 day moving average price of $11.22.

TG Therapeutics Company Profile

(Get Rating)

TG Therapeutics, Inc engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.